These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25804827)

  • 1. American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma.
    Glavey SV; Ghobrial IM
    Expert Rev Hematol; 2015 Jun; 8(3):273-5. PubMed ID: 25804827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017.
    Terpos E;
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):321-334. PubMed ID: 29576386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.
    Saburi M; Ogata M; Soga Y; Kondo Y; Kurimoto R; Itani K; Kohno K; Uchida H; Nakayama T
    J Clin Exp Hematop; 2020; 60(1):17-20. PubMed ID: 32224561
    [No Abstract]   [Full Text] [Related]  

  • 4. 57th American Society of Hematology Annual Meeting.
    Smith LL
    Lancet Oncol; 2016 Feb; 17(2):142. PubMed ID: 26687594
    [No Abstract]   [Full Text] [Related]  

  • 5. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
    Kunacheewa C; Manasanch EE
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma.
    Richard S; Jagannath S; Cho HJ; Parekh S; Madduri D; Richter J; Chari A
    Expert Rev Hematol; 2021 Jan; 14(1):31-45. PubMed ID: 33331794
    [No Abstract]   [Full Text] [Related]  

  • 7. Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
    Holstein SA; Al-Kadhimi Z; Costa LJ; Hahn T; Hari P; Hillengass J; Jacob A; Munshi NC; Oliva S; Pasquini MC; Shi Q; Stadtmauer EA; Waldvogel SL; McCarthy PL
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):e7-e15. PubMed ID: 31526843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018.
    Terpos E; Ntanasis-Stathopoulos I;
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e324-e336. PubMed ID: 31076371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016.
    Terpos E;
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):329-339. PubMed ID: 28462890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacologic management of multiple myeloma in older adults.
    Dempsey JL; Johns A; Rosko AE; Lazarus HM
    Expert Opin Pharmacother; 2019 May; 20(7):887-902. PubMed ID: 30785310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geriatric Hematology Research presented at the 2018 American Society of Hematology Annual Meeting: Young International Society of Geriatric Oncology Perspective Paper.
    Loh KP; Christofyllakis K; Huang LW; Mims A
    J Geriatr Oncol; 2019 Mar; 10(2):186-191. PubMed ID: 30661875
    [No Abstract]   [Full Text] [Related]  

  • 12. Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data.
    Weisel K; Ludwig H; Rieth A; Lebioda A; Goldschmidt H
    Qual Life Res; 2020 Jan; 29(1):69-79. PubMed ID: 31552577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.
    Holstein SA; Avet-Loiseau H; Hahn T; Ho CM; Lohr JG; Munshi NC; Paiva B; Pasquini MC; Tario JD; Usmani SZ; Wallace PK; Weisel K; McCarthy PL
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):641-648. PubMed ID: 29242112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 49th Annual Meeting of the American Society of Hematology, Atlanta, GA; December 8-11, 2007.
    Clin Lymphoma Myeloma; 2008 Apr; 8(2):77-86. PubMed ID: 18564453
    [No Abstract]   [Full Text] [Related]  

  • 15. American Society of Clinical Oncology 41st annual meeting.
    Dillman RO
    Expert Opin Biol Ther; 2005 Aug; 5(8):1117-27. PubMed ID: 16050788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A Podcast.
    Costa LJ; Rodriguez-Otero P
    Adv Ther; 2024 Aug; 41(8):3017-3027. PubMed ID: 38642197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
    van de Donk NW; Lokhorst HM
    Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma.
    Touzeau C; Antier C; Moreau P
    Future Oncol; 2021 Mar; 17(9):993-998. PubMed ID: 33289427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
    San-Miguel J; Avet-Loiseau H; Paiva B; Kumar S; Dimopoulos MA; Facon T; Mateos MV; Touzeau C; Jakubowiak A; Usmani SZ; Cook G; Cavo M; Quach H; Ukropec J; Ramaswami P; Pei H; Qi M; Sun S; Wang J; Krevvata M; DeAngelis N; Heuck C; Van Rampelbergh R; Kudva A; Kobos R; Qi M; Bahlis NJ
    Blood; 2022 Jan; 139(4):492-501. PubMed ID: 34269818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.
    Højholt KL; Gregersen H; Szabo AG; Klausen TW; Levring MB; Preiss B; Helleberg C; Breinholt MF; Hermansen E; Rahbek Gjerdrum LM; Bønløkke ST; Nielsen K; Kjeldsen E; Iversen KF; Teodorescu EM; Kurt E; Strandholdt C; Andersen MK; Vangsted AJ
    Hematol Oncol; 2021 Oct; 39(4):521-528. PubMed ID: 34342035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.